Tag Archives: SOLOIST

Lexicon @ Stifel; First Presentation Since SOLOIST and SCORED Results

Lexicon participated in the 2020 Stifel Virtual Healthcare Conference and provided brief updates on its sotagliflozin strategy following the data readout from SOLOIST and SCORED. In case you missed it, here is a link to FENIX’s initial thoughts on the data. Below, FENIX provides highlights from Lexicon senior management’s commentary as well as an updated perspective and implications to sotagliflozin’s commercial prospects.

This content is for Read Less members only.
Register
Already a member? Log in here

Lexicon Wins Big with SOLOIST and SCORED

Late yesterday, results from the sotagliflozin CVOTs (SOLOIST-WHF and SCORED) were presented at the AHA 2020 conference (view press release) and simultaneously published in the NEJM (SOLOIST-WHF publication and SCORED publication). Somewhat surprisingly, both trials demonstrated highly statistically significant CV benefits despite the fact that they were closed early due to financial and strategic reasons (previous FENIX insight). Below, FENIX provides an overview of the SOLOIST and SCORED results as well as implications to the SGLT2i class and beyond.

This content is for Read Less members only.
Register
Already a member? Log in here

First Results for Bayer’s FIDELIO @ Kidney Week; ASN High-impact Trials Released

On Friday Oct 9, ASN posted more sessions for Virtual Kidney Week. Importantly, Bayer’s FIDELIO-DKD trial for finerenone will seemingly have first results presented during Kidney Week, rather than at Virtual AHA (previous FENIX insight). Below, FENIX provides a bit more detail and thought on a dynamic 3-4 weeks between Kidney Week and AHA.

This content is for Read Less members only.
Register
Already a member? Log in here

Sotagliflozin, Finerenone, and Omecamtiv CVOTs @ AHA 2020

The AHA 2020 late-breaking abstract titles have been published and include the sotagliflozin (SOLOIST-WHF and SCORED), finerenone (FIDELIO-DKD), and omecamtiv mecarbil (GALACTIC-HF) CVOTs (view all AHA late-breaking topics here). Recall, Bayer announced positive topline results from FIDELIO-DKD in July 2020 (previous FENIX insight). Lexicon has not released any topline results from the SOLOIST-WHF and SCORED trials, which were closed out early following the Sanofi partnership dissolution (previous FENIX insight). As such, the SCORED and SOLOIST-WHF results are highly anticipated.

This content is for Read Less members only.
Register
Already a member? Log in here